Blog

Amryt Pharmaceuticals PLC licenses gene therapy platform from … – Proactive Investors UK


Proactive Investors UK

Amryt Pharmaceuticals PLC licenses gene therapy platform from …
Proactive Investors UK
Amryt Pharma PLC (LON:AMYT) has licensed a non-viral gene therapy platform technology with potential applicability across a range of genetic diseases, including epidermolysis-bullosa (EB). The technology has been licensed from University College Dublin
Irish biopharma company and UCD to use gene therapy for rare skin disorderSiliconrepublic.com


Rare disease firm Amryt reveals a "major" gene therapy tie-up as revenues riseCity A.M.
Amryt reports strong 2017 as revenues rise to almost €13mIrish Times

all 8 news articles »

2018-03-15 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.